325.82
前日終値:
$319.71
開ける:
$322.99
24時間の取引高:
317.00K
Relative Volume:
0.68
時価総額:
$14.70B
収益:
$2.99B
当期純損益:
$1.21B
株価収益率:
13.00
EPS:
25.06
ネットキャッシュフロー:
$1.13B
1週間 パフォーマンス:
+2.19%
1か月 パフォーマンス:
+10.44%
6か月 パフォーマンス:
-11.86%
1年 パフォーマンス:
+17.88%
United Therapeutics Corp Stock (UTHR) Company Profile
名前
United Therapeutics Corp
セクター
電話
(301) 608-9292
住所
1000 SPRING ST, SILVER SPRING, MD
UTHR を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
UTHR
United Therapeutics Corp
|
325.82 | 14.45B | 2.99B | 1.21B | 1.13B | 25.06 |
![]()
HLN
Haleon Plc Adr
|
11.07 | 50.98B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
ZTS
Zoetis Inc
|
170.16 | 74.41B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
RDHL
Redhill Biopharma Ltd Adr
|
1.99 | 4.03M | 35.75M | 11.57M | -26.25M | -3.8069 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.96 | 46.23B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.77 | 20.10B | 16.54B | -1.64B | 749.00M | -1.45 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-06-02 | 開始されました | Cantor Fitzgerald | Overweight |
2025-04-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
2025-04-21 | アップグレード | BofA Securities | Underperform → Neutral |
2024-07-11 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2024-02-12 | アップグレード | Goldman | Sell → Neutral |
2024-02-05 | 開始されました | Leerink Partners | Outperform |
2023-12-08 | 開始されました | Wells Fargo | Overweight |
2022-12-06 | 開始されました | UBS | Buy |
2022-12-05 | 開始されました | Goldman | Sell |
2022-10-11 | 開始されました | Morgan Stanley | Overweight |
2022-09-20 | 繰り返されました | BofA Securities | Underperform |
2022-09-19 | 再開されました | Wedbush | Outperform |
2022-02-11 | 開始されました | BTIG Research | Neutral |
2021-07-14 | アップグレード | Argus | Hold → Buy |
2021-04-26 | 再開されました | Credit Suisse | Outperform |
2021-02-01 | アップグレード | H.C. Wainwright | Neutral → Buy |
2020-09-14 | 再開されました | JP Morgan | Overweight |
2020-06-25 | 繰り返されました | H.C. Wainwright | Neutral |
2020-03-10 | アップグレード | Jefferies | Hold → Buy |
2020-02-27 | アップグレード | Cowen | Market Perform → Outperform |
2020-01-31 | アップグレード | JP Morgan | Neutral → Overweight |
2019-12-03 | 開始されました | BofA/Merrill | Underperform |
2019-08-01 | アップグレード | Jefferies | Underperform → Hold |
2019-08-01 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
2019-07-01 | アップグレード | Credit Suisse | Neutral → Outperform |
2019-05-17 | アップグレード | UBS | Sell → Neutral |
2019-05-09 | アップグレード | Credit Suisse | Underperform → Neutral |
2018-10-12 | アップグレード | Standpoint Research | Hold → Buy |
2018-08-08 | ダウングレード | Credit Suisse | Neutral → Underperform |
2018-04-03 | アップグレード | Credit Suisse | Underperform → Neutral |
2018-02-22 | 繰り返されました | Barclays | Underweight |
2018-01-18 | 再開されました | Credit Suisse | Underperform |
2017-12-27 | 繰り返されました | Wedbush | Outperform |
2017-04-27 | 繰り返されました | Wedbush | Outperform |
2017-03-30 | 開始されました | UBS | Sell |
2017-03-16 | 開始されました | Credit Suisse | Underperform |
すべてを表示
United Therapeutics Corp (UTHR) 最新ニュース
Leerink Partners maintains positive outlook on United Therapeutics stock By Investing.com - Investing.com South Africa
Leerink Partners maintains positive outlook on United Therapeutics stock - Investing.com
United Therapeutics (NASDAQ:UTHR) Now Covered by Cantor Fitzgerald - Defense World
United Therapeutics (UTHR) Receives New Overweight Rating from Cantor Fitzgerald | UTHR Stock News - GuruFocus
Forecasting The Future: 7 Analyst Projections For United Therapeutics - Benzinga
United Therapeutics (UTHR) Receives Overweight Rating from Canto - GuruFocus
United Therapeutics (UTHR) Receives Overweight Rating from Cantor Fitzgerald | UTHR Stock News - GuruFocus
Ex-United Therapeutics Exec Can't Dodge IP Suit - Law360
United Therapeutics Co. (NASDAQ:UTHR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Those who invested in United Therapeutics (NASDAQ:UTHR) five years ago are up 151% - Yahoo
Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge - Benzinga
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 - Yahoo Finance
Eisenmenger Complex Treatment Market 2032: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - Barchart.com
FDA Approves Liquidia Corporation (LQDA)’s YUTREPIA Amid Patent Dispute - Insider Monkey
Zacks Research Has Pessimistic Outlook of UTHR Q2 Earnings - Defense World
FDA Approves Liquidia's (LQDA) Yutrepia, Court Ruling Pending - GuruFocus
U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) - GlobeNewswire Inc.
Zacks Research Issues Negative Estimate for UTHR Earnings - Defense World
HHS layoffs create ‘clear opportunity’ for local health, life sciences companies to add talent - The Business Journals
Liquidia Says UTC Can’t Stop Its New Lung Drug From Launching - Bloomberg Law News
Construction underway for new United Therapeutics facility in Stewartville - KTTC News
Stewartville pig-to-human transplant facility to be complete in 2026 - Post Bulletin
Interesting UTHR Put And Call Options For July 18th - Nasdaq
Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses - Yahoo Finance
UTHR Q1 Earnings Call: Double-Digit Growth Continues, Pipeline Expansion Remains Central - Yahoo Finance
UTC Again Seeks To Stave Off Lung Drug Competitor In IP Suit - Law360
Liquidia Faces Patent Litigation Filed by United Therapeutics - marketscreener.com
Liquidia (LQDA) Faces Patent Infringement Lawsuit from United Th - GuruFocus
Liquidia Says New Litigation Filed Against Co In U.S. - marketscreener.com
Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics - Yahoo Finance
Is United Therapeutics (UTHR) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies? - Insider Monkey
Liquidia Corp (LQDA) Q1 2025 Earnings Call Highlights: Strategic Advances and Legal Wins Propel ... - Yahoo Finance
3 Big Reasons to Love United Therapeutics (UTHR) - Yahoo Finance
MANNKIND CORP SEC 10-Q Report - TradingView
Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance
TD Cowen maintains United Therapeutics stock Buy rating By Investing.com - Investing.com Nigeria
TD Cowen maintains United Therapeutics stock Buy rating - Investing.com
3 Market-Beating Stocks with Solid Fundamentals - Yahoo Finance
United Therapeutics (UTHR) Target Price Lowered by Argus, Retains Buy Rating | UTHR Stock News - GuruFocus
Liquidia Fends Off Indication Challenge In UTC Tyvaso Fight - Law360
United Therapeutics (UTHR) Receives Reiterated "Buy" Rating from HC Wainwright | UTHR Stock News - GuruFocus
US judge dismisses United Therapeutics' counterclaims over Liquidia's 'Yutrepia' - MLex
United Therapeutics (UTHR) Gets a Hold from Wells Fargo - The Globe and Mail
Legal Victory: Liquidia Clears Major Hurdle for YUTREPIA Dual-Indication Approval This Month - Stock Titan
BofA raises United Therapeutics stock target to $321 - Investing.com Australia
United Therapeutics (UTHR): Morgan Stanley Raises Price Target | - GuruFocus
BofA raises United Therapeutics stock target to $321 By Investing.com - Investing.com Canada
United Therapeutics (UTHR) Analyst Update: JP Morgan Maintains R - GuruFocus
United Therapeutics (UTHR) Analyst Update: JP Morgan Maintains Rating | UTHR Stock News - GuruFocus
United Therapeutics (UTHR): Morgan Stanley Raises Price Target | UTHR Stock News - GuruFocus
Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insig - GuruFocus
United Therapeutics Corp (UTHR) 財務データ
収益
当期純利益
現金流量
EPS
United Therapeutics Corp (UTHR) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
EDGEMOND JAMES | CFO AND TREASURER |
Jun 02 '25 |
Sale |
325.82 |
12,000 |
3,909,893 |
8,118 |
大文字化:
|
ボリューム (24 時間):